SUPN — SUPERNUS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356576 ·
Last close
$47.77
Market Cap
$2.77B
52W High
$56.59
52W Low
$46.83
ADV30
676,292
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 207,705,000 | 184,314,000 | -5,941,000 | -2,293,000 | 1,500,725,000 | 184,869,000 | 423,920,000 |
| Dec 2025 | 211,572,000 | 188,565,000 | 13,822,000 | -4,105,000 | 1,452,648,000 | 128,448,000 | 390,934,000 |
| Sep 2025 | 192,103,000 | 173,138,000 | -60,231,000 | -45,117,000 | 1,419,754,000 | 151,371,000 | 370,087,000 |
| Jun 2025 | 165,453,000 | 148,626,000 | 12,141,000 | 22,499,000 | 1,382,405,000 | 144,711,000 | 318,505,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$47,331,000
Investing CF
$4,106,000
Financing CF
$9,130,000
CapEx
$-1,338,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.68
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$517,876,000
Inventory
$82,385,000
Receivables
$187,802,000
ST Investments
$180,222,000
EBIT TTM
$-49,030,000
Pretax Income TTM
$-49,030,000
Interest Exp TTM
$0
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$776,833,024
EBITDA
$122,628,000
Free Cash Flow
$132,620,496
Enterprise Value
$2,454,756,864
Total Cash
$384,240,992
Total Debt
$40,903,000
Shares Out
58,039,721
Trailing EPS
$-0.51
Book Value
$18.48
ROE
-2.8%
ROA
1.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 718,952,000 | -36,864,000 | -38,550,000 | 1,452,648,000 | 390,934,000 | — | 47,331,000 |
| Dec 2024 | 661,817,000 | 75,556,000 | 73,865,000 | 1,368,073,000 | 332,340,000 | — | 171,951,000 |
| Dec 2023 | 607,521,000 | 13,403,000 | 1,316,000 | 1,277,673,000 | 356,157,000 | — | 111,085,000 |
| Dec 2022 | 667,238,000 | 45,614,000 | 60,711,000 | 1,702,508,000 | 816,304,000 | — | 116,826,000 |
TTM Snapshot
Revenues TTM
$655,386,000
NetIncome TTM
$45,832,000
OpCashFlow TTM
$0
Assets (Latest)
$1,368,073,000
Forward EPS
$4.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLNO | SOLENO THERAPEUTICS INC | $2.76B | $53.01 | — |
| ALMS | ALUMIS INC. | $2.76B | $22.33 | — |
| KLRA | Kailera Therapeutics, Inc. | $2.79B | $21.57 | — |
| GPCR | Structure Therapeutics Inc. | $2.81B | $39.58 | — |
| TNGX | Tango Therapeutics, Inc. | $2.90B | $20.04 | — |
News headlines (Yahoo Finance, 1h cache)
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate
2026-05-24 12:11 · Yahoo
3 Stocks Under $50 with Open Questions
2026-05-22 21:16 · Yahoo
3 Small-Cap Stocks That Concern Us
2026-05-20 05:32 · Yahoo
3 Growth Stocks We Approach with Caution
2026-05-19 09:56 · Yahoo
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call
2026-05-15 09:40 · Yahoo
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
2026-05-12 17:10 · Yahoo
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
2026-05-06 21:00 · Yahoo
Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)?
2026-05-06 17:15 · Yahoo
Supernus Pharmaceuticals Q1 Earnings Call Highlights
2026-05-06 03:09 · Yahoo
Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-06 00:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.